ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkins Lymphoma: A Single Center Experience.
10.3904/kjim.2006.21.3.159
- Author:
Sang Hyoung PARK
1
;
Shin KIM
;
Ok Bae KO
;
Ja Eun KOO
;
Danbi LEE
;
Yong Pil JEONG
;
Jooryung HUH
;
Sung Bae KIM
;
Sang We KIM
;
Jae Lyun LEE
;
Cheolwon SUH
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. csuh@amc.seoul.kr
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Lymphoma;
Non-Hodgkin;
Salvage therapy;
ESHAP regimen
- MeSH:
Treatment Failure;
Survival Analysis;
*Salvage Therapy;
Prednisone;
Neoplasm Recurrence, Local/*drug therapy/mortality;
Middle Aged;
Methylprednisolone/administration & dosage;
Male;
Lymphoma, Non-Hodgkin/*drug therapy/mortality/pathology;
Humans;
Female;
Etoposide/administration & dosage;
Disease Progression;
Cytarabine/administration & dosage;
Cisplatin/administration & dosage;
*Antineoplastic Combined Chemotherapy Protocols;
Antineoplastic Agents/administration & dosage;
Aged;
Adult;
Adolescent
- From:The Korean Journal of Internal Medicine
2006;21(3):159-164
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to determine whether ESHAP therapy would be effective and well-tolerated in Korean patients. METHODS: Twenty two patients with refractory or relapsed NHLs (all aggressive types) were enrolled in this study. We retrospectively evaluated the treatment response, the survival rate and the time to progression. RESULTS: Six patients (27.3%) attained complete remission and eight patients (36.4%) attained partial remission. The overall response rate was 63.6%. The median survival duration was 15.5 months (95% confidence interval; 10.7 to 20.3 months), and the median duration of the time to progression was 8.3 months (95% confidence interval; 0.3 to 16.3 months). Myelosuppression was the major toxicity, but severe neutropenia or thrombocytopenia was rare, and renal toxicity was also infrequent. CONCLUSIONS: ESHAP regimen is effective in Korean patients suffering with relapsed or refractory NHLs, but a more effective salvage modality is needed because of the short duration of remission and the insignificant impact on long-term survival.
